Molecular Cancer is a peer-reviewed open-access medical journal covering basic and translational research in oncology and molecular biology.《分子癌症》（Molecular Cancer）是一本经同行评审的开放获取医学期刊，主要涵盖肿瘤学和分子生物学领域的基础与转化研究。 Published by BioMed Central (part of Springer Nature), the journal aims to advance molecular insights into the mechanisms of carcinogenesis, progression, and potential therapeutic interventions.该期刊由生物医学中心（BioMed Central，隶属于施普林格·自然）出版，旨在促进对癌症发生、发展及潜在治疗机制的分子水平理解。
The journal publishes original research articles, reviews, short communications, and commentaries covering all aspects of cancer biology.该期刊发表涉及肿瘤生物学各个方面的原始研究论文、综述、快报和评论。 Key topics of interest include oncogene and tumor suppressor function, the tumor microenvironment, non-coding RNA regulatory networks, cancer metabolism, mechanisms of drug resistance, and tumor metastasis.其关注的核心主题包括致癌基因与抑癌基因的功能、肿瘤微环境、非编码RNA调控网络、癌症代谢、耐药机制以及肿瘤转移。 Additionally, the journal emphasizes biomarker discovery and personalized targeted therapeutic strategies based on genomics, proteomics, and single-cell sequencing technologies.此外，该刊重点关注基于基因组学、蛋白质组学及单细胞测序技术的生物标志物发现与个性化靶向治疗策略。
Molecular Cancer was established in 2002 as one of the early open-access oncology journals launched by BioMed Central.《分子癌症》创刊于2002年，是生物医学中心最早创办的开放获取肿瘤学学术期刊之一。 As global biomedical research transitioned toward open-access publishing models, the journal's publication volume and academic influence grew steadily over the past two decades.随着全球生物医药研究向开放获取模式转型，该期刊的年发文量和学术影响力在过去二十年中持续上升。 The journal operates entirely online, offering researchers worldwide a rapid peer-review process and immediate free access to published findings.该刊采用全数字出版形式，为全球科研人员提供快速的同行评审流程和全球范围内的免费获取途径。
The founding Editor-in-Chief was Dr. Michael A. Tainsky from the Barbara Ann Karmanos Cancer Institute at Wayne State University.创刊主编为韦恩州立大学芭芭拉·安·卡马诺斯癌症研究所的迈克尔·A·坦斯基（Michael A. Tainsky）博士。 The journal's editorial board consists of leading international scholars from prestigious universities and cancer centers, spanning fields such as cancer genetics, signal transduction, and experimental therapeutics.该期刊的编辑委员会由来自全球顶尖大学与癌症研究中心的资深学者组成，涵盖肿瘤遗传学、信号转导和实验治疗学等多个专业领域。 The editorial team oversees the rigorous peer-review process, supported by associate editors and editorial board members who ensure scientific rigor and ethical compliance.编辑团队负责监督严格的双盲或单盲同行评审流程，并由专业的副主编和编委会成员共同把关稿件的学术质量与学术伦理合规性。